Skip to main content
Clinical Trials/ChiCTR1800015340
ChiCTR1800015340RecruitingPhase 4

基于药代动力学,药物基因组学的经鼻给予右美托咪定患儿个体化给药研究

Not provided1 site in 1 country96 target enrollmentStarted: March 28, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Enrollment
96
Locations
1
Primary Endpoint
血药浓度

Study Overview

Brief Summary

探究 0-6 岁患儿中影响经鼻给予右美托咪定药物作用疗效的基因以及代谢的相关因素

Study Design

Study Type
Observational

Eligibility Criteria

Ages
0 to 6 (—)
Sex
All

Inclusion Criteria

  • 所有诊断为血管瘤需要实行全身麻醉的 ASA 分级在 I-II, 年龄在 0-6 岁的患儿将纳入实验

Exclusion Criteria

  • 包括 ASA 3 级以上的对右美托咪定过敏和有流涕的患儿

Arms & Interventions

Case series

右美托咪定

Intervention: 右美托咪定

Outcomes

Primary Outcomes

血药浓度

镇静成功率

基因检测

Secondary Outcomes

  • 血压
  • 心率

Investigators

Study Sites (1)

Loading locations...

Similar Trials

基于药代动力学,药物基因组学的经鼻给予右美托咪定患儿个体化给药研究 | Clinical Trial